Immatics' T-Cell Redirecting Immunotherapies Impress In Solid Tumors
Quicker Cell Engineering Could Be Key
The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.
You may also be interested in...
Deal Snapshot: GSK obtains rights to two of Immatics’ TCR targets, following on the German firm’s similar deals in recent years with Celgene, Genmab and Amgen.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.